UBx is the lead institution for the Decide TB project. Within the Bordeaux Population Health research centre at UBx, the Global Health in the Global South (GHiGS) team works on the prevention and treatment of infectious diseases (HIV, tuberculosis, viral hepatitis, Ebola, Lassa, malaria, bacterial resistance), maternal and child health, and non-communicable diseases including malnutrition in Africa.

GHiGS aims at:
i) providing clinical and epidemiological data at individual and population-level, and conducting public health, community-based, as well as social sciences research;
ii) designing and evaluating innovative interventions to improve health outcomes in resource-constrained settings.

It currently supervises 14 PhD students, 7 of whom are African. GHiGS conducts high quality research in up to 30 countries including clinical trials, diagnostic cohorts, operational and implementation research.

Large studies in the field of infectious diseases (Temprano, TasP, TB-Speed) or malnutrition (Optima) have had an important impact at international level and contributed to WHO policy. GHiGS (Olivier Marcy, team director) was the coordinator of the TB-Speed study.

NTP MZ is the entity of the Ministry of Health that coordinates tuberculosis control actions in the country.
TB services are integrated into the National Health Service and System and decentralized throughout the network up to community level. About 27% have TB diagnostic units distributed at the primary, secondary and tertiary levels, 8% have chest X-ray equipment and 70% of health units manage and monitor TB patients.

NTP Mozambique activities include the following components:
i) Community-engagement;
ii) TB/HIV Collaborative Activities that are supported by a technical group composed of different partners (e.g. CDC, Ariel Glaser, EGPAF, USAID);
iii) Care and Treatment for child TB, sensitive and Multi-Drug Resistant TB, which includes implementation research and pilot studies on short regimen for MDR-TB (B-Plus) and 3HP latent TB treatment and responsibility for developing guidelines for the clinical management of TB (13 manuals developed in 15 years). This receives support from a technical group (HIV-Program, MNCH, Ariel Glaser Foundation, USAID, CDC, UCLA);
iv) Management of Medicines and Laboratory Supplies;
v) Monitoring and Evaluation, Research and Innovation: which includes development of patient-based electronic records.

INS is a public entity for management, regulation and supervision of activities related to the generation of scientific evidence in Health in Mozambique and assumes its position in the resolution of the problem of tuberculosis in the country.
It was created, among others, to promote the development of research in Health and carry out clinical, biomedical, pharmacological, epidemiological, operational, socio-anthropological and health systems research, based on national priorities.
INS is currently led by a General Board comprised by the General Director, Deputy-General Director and four National Directors for the area of Health and Welfare Research, Public Health Laboratories, Training and Communication in Health and Inquiries and Health Observation.
The Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC) is arm of the Instituto Nacional de Saúde within Maputo City to conduct clinical research program in the field of tuberculosis.
The INS/CISPOC team led by Dr Celso Khosa contributed to the TB-Speed Decentralization, HIV, and Pneumonia studies, and to the RaPaed-TB study.

The PAC-CI program is a research center with the status of a “non-governmental organization (NGO),” created in 1996 as a result of cooperation between Côte d’Ivoire and France. This research center is governed by an agreement between these two countries with:

– For Côte d’Ivoire, the Ministry of Health and Public Hygiene, the Ministry of Higher Education and Scientific Research, and the Ministry of Economy and Finance
– For France, the National Agency for Research on HIV/AIDS and Viral Hepatitis (ANRS-REACTING), the National Institute of Health and Medical Research, the University of Bordeaux, and the Ministry of Foreign Affairs.

The PAC-CI program is a leader in the field of health research, with research projects on the HIV/AIDS epidemic, viral hepatitis, maternal and child health, tuberculosis, and more recently, infectious diseases with endemic potential.Our mission is to:Conduct health research activities whose results will be useful to infected and affected populationsPromote the training of health professionals in medical research
The PAC-CI program takes a multidisciplinary approach, drawing on clinical sciences, epidemiology and public health, biology, demography, sociology, anthropology, applied economics, and statistical modeling to understand the health problems of populations and propose solutions.Academic and technical training is a major focus of our organization, which targets both Master’s and PhD students and research support staff.

The National Tuberculosis Control Programme (PNLT) is the governmental body responsible for coordinating the fight against tuberculosis in Côte d’Ivoire. Established by decree in 2001, it aims to prevent, diagnose, and treat TB nationwide, with the long-term goal of eliminating it as a public health threat. The programme operates through a three-tier system — central, regional, and peripheral — ensuring implementation of activities across the country.

Its main components include:
– monitoring and evaluation,
– laboratory services,
– patient care and capacity building,
– procurement and drug supply,
– communication and community engagement,
– TB/HIV co-management,
– management of drug-resistant TB,
– administrative and financial affairs.

At the central level, the PNLT defines strategic orientations, coordinates national and international partners, and guides national policy. Regional and local teams ensure supervision of TB units, case management, and community-based detection and follow-up. The PNLT also leads awareness campaigns and access-to-care initiatives to reduce TB morbidity, mortality, and treatment loss to follow-up.

UNZA is the co-lead for Decide-TB. UNZA is a public university established by Act of the Zambian Parliament in 1964.
It is the largest university and leading research institution in Zambia. The School of Medicine is situated at a separate campus at the site the University teaching Hospital (UTH).
The institution offers other undergraduate and post graduate degree programs in Pharmacy, Nursing Sciences, Biomedical Sciences, Physiotherapy, Environmental and Public Health. The UNZA/UTH has a long history of local and collaborative research which has influenced policy and practice and has greatly contributed to quality clinical services.
The institution is a hub for paediatric TB and HIV research and has participated in a number of multicentre collaborative research.
This research team has previously implemented impactful paediatric TB and HIV research including the SHINE and CHAPAS 1,2 and 3 trials and more recently the multicounty TB-Speed research project.
The team was a recipient 2018 EDCTP outstanding research team award given to the CHAPAS consortium.

SU is one of the three highest ranked universities in Africa and is home to about 29,000 students from 100 different countries.
SU is a leading research-intensive higher education institution in Africa and is recognized as one of the three top research universities in South Africa with of the country’s highest proportions of postgraduate students and with most personnel research publications in South Africa.
Research at SU is driven by the notions of simultaneous excellence and relevance, informed by a diversity of people and ideas.
SU is internationally acknowledged as a world leader in the field of TB research (as confirmed by, inter alia, the global bibliometric co-citation analyses done via the Elsevier Scopus SciVal Spotlight Tool, identifying this as an area of unique competency at SU).
The research field with the top number of publications involving SU researchers is TB, where SU is the leading African university.
The Desmond Tutu TB centre (DTTC) is based within SU and is internationally renowned for excellence in the field of paediatric TB research.
DTTC’s expertise is based around three strategic research focal areas: Paediatric TB; Health Systems, Implementation and Operational Research; and HIV prevention through Community Randomized Trials, including a strong focus on high quality socio-behavioural research.

Médecins Sans Frontières Logistique (MSF Logistique) is the logistical and procurement arm of the MSF movement, responsible for sourcing, storing, and shipping medical and non-medical supplies to MSF’s field operations and, in certain cases, to other humanitarian actors.
Climate Action Accelerator

Founded in 1986, MSF Logistique was created to meet the mounting logistical demands of MSF missions.
Médecins Sans Frontières
It operates warehouses, handles product cataloguing, and ensures rapid dispatch of equipment and medicines, especially in emergencies.
Its supply chain spans across MSF’s central hubs, field bases, and purchasing centers.

In emergency contexts, MSF Logistique maintains “pre-packaged kits” — ready-to-deploy packages (e.g. surgical kits, obstetric kits) — that can be dispatched by air within 24 hours.
MEDECINS SANS FRONTIERES – MIDDLE EAST

Based in Mérignac, France, with additional presence in Dubai, MSF Logistique is one of MSF’s main purchasing and supply centers.
In 2021, it managed over 14,500 catalogue references, shipped more than 6,000 tonnes, and recorded a turnover of about €121 million.
Climate Action Accelerator

MSF Logistique also engages in efforts to improve sustainability: it has committed to reducing the environmental impact of its procurement and supply operations, notably through a “green roadmap” in collaboration with the Climate Action Accelerator.

ADERA (Association for Research and Innovation Support in Nouvelle-Aquitaine) acts as a bridge between public research labs and private industry in southwestern France. It supports companies and academic laboratories by offering strategic consulting, legal and administrative assistance, human resources, financial and project management services, as well as organizing congresses, workshops and training sessions.

ADERA has already assisted over 200 laboratories and 500 companies. It manages more than 30 technological platforms and research “cells,” oversees partnerships and collaborative R&D contracts (public-private), and invests in technology startups—being a founding shareholder of Pertinence Invest. It is ISO 9001 certified for its management activities since 2013.

Additionally, ADERA is an accredited training organization, delivers continuing education in scientific and technical fields, and handles full event logistics from registration to on-site coordination. Its mission is to strengthen the research & innovation ecosystem in Nouvelle-Aquitaine by providing expert support and operational capabilities.